









市場行情
/
股票
/
nasdaq-aray
/

Accuray Inc

ARAY



查看詳細走勢圖

0.907USD

+0.019+2.16%

收盤 12/19, 16:00（美東）報價延遲15分鐘

102.80M總市值

虧損本益比TTM



Accuray Inc

0.907

+0.019+2.16%

概覽公司財務分析

概覽

公司

財務

分析

盤中分時

1分

30分

1小時

日k

週k

月k

日k

今天

+2.16%

5天

-14.39%

1月

-13.57%

6月

-25.61%

今年開始到現在

-54.17%

1年

-50.95%

查看詳細走勢圖

TradingKey Accuray Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Accuray Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名85/208位。機構持股佔比非常高，近一個月多位分析師給出公司評級為強力買入。最高目標價3.88。中期看，股價處於下降通道。近一個月，市場表現較差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。

Accuray Inc評分

壓力支撐

由於公司未披露，未能獲取相關數據

多維評測

本期評分

上期評分

分析師目標

基於 2 分析師

強力買入

評級

3.875

目標均價

+292.13%

漲幅空間

數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議

Accuray Inc亮點

亮點風險

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells and supports solutions that are designed to deliver radiation treatments for complex cases. Its solutions are designed to advance patient care: during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, it also provides services, which include post-contract customer support (warranty period services and post-warranty services), installation services, training, and other professional services.

估值高估

公司最新PE估值-5.73，處於3年歷史高位

機構減倉

最新機構持股79.19M股，環比減少0.02%

PRFDX持倉

明星投資者PRFDX持倉，最新持倉10.25K股